VALBIOTIS will present the results of its Phase I/II clinical study on the active ingredient of Valedia®, TOTUM-63, during the 77th Scientific Sessions of the American Diabetes Association.
VALBIOTIS Initial Public Offering records huge success
Sébastien PELTIER, CEO of VALBIOTIS, presents his vision of diabetes-free world at l’Echappée Volée
Two partnership agreements to assess the effects of TOTUM-63, the active ingredient Valedia®, on intestinal microbiota
VALBIOTIS at the 77th scientific sessions of the American Diabetes Association